Abstract
There has been growing concern about high risk of airborne infection during wind instrument performance as the COVID-19 pandemic evolves. In collaboration with 16 musicians from the Minnesota Orchestra, we employ multiple experimental and numerical techniques to quantify the airflow and aerosol concentration emitted from ten wind instruments under realistic performance conditions. For all instruments, the extent of the flow and aerosol influence zones are limited to 30 cm. Further away, the thermal plume generated by the human body is the dominant source of flow. Flow and aerosol concentration vary in response to changes in music amplitude, pitch, and note duration, depending on playing technique and instrument geometry. Covering the trumpet bell with speaker cloth and placing filters above the instrument outlet can substantially reduce the aerosol concentration. Our findings indicate that with appropriate risk mitigation strategies, musical instrument performance can be conducted with low risk of airborne disease transmission.
Competing Interest Statement
MW is employed by the Minnesota Orchestra. No other relationships or activities that could appear to have influenced the submitted work.
Funding Statement
This work was supported by the School of Medicine of the University of Minnesota
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The University of Minnesota provided IRB approval for this study (HSIRB STUDY00009795)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.